The rhesus incompatible pregnancy and its consequences for affected fetuses and neonates
Introduction
Rhesus incompatibility in pregnancy is the discordance between maternal and fetal red cell antigens belonging to the Rhesus blood group system (most commonly D, E, e, C & c). Maternal alloimmunisation to antigens on fetal erythrocytes can result in the significant and potentially fatal consequence of haemolytic disease of the fetus and newborn (HDFN). A significant reduction in the prevalence of maternal alloimmunisation to the D antigen has resulted where widespread use of anti-D immune globulin prophylaxis has been implemented for Rhesus-D negative pregnant women. Despite this, Rhesus incompatibility in pregnancy continues to contribute to perinatal morbidity and mortality worldwide. With the availability of modern surveillance techniques and expert therapeutic interventions, consequences of the disease and its treatment are minimised, and the overall outcomes for the fetus and neonate are favourable [1].
Section snippets
Pathogenesis and natural history of HDFN
The pathophysiology underlying HDFN stems from discordance between maternal and fetal red cell antigens. Fetal red cells with paternally inherited surface antigens may enter the maternal circulation during pregnancy or at the time of delivery. Some episodes of fetal-maternal haemorrhage occur in sufficient volumes to cause a maternal immune response to the foreign antigens on fetal erythrocytes. This is well recognised where a Rhesus-D negative woman forms antibodies to a paternally inherited D
Fetal and postnatal outcomes associated with HDFN and its management
Whilst the natural history of severe Rhesus alloimmunisation confers a poor outlook for the fetus and neonate, the trajectory of the disease has been significantly altered by modern management. Significant reduction in the prevalence of Rhesus-D alloimmunisation has occurred as a result of anti-D prophylaxis. Widespread screening for maternal alloantibodies during pregnancy allows for surveillance of at-risk pregnancies and earlier detection of fetal anaemia. Advances in non-invasive
Conclusion
Left untreated, haemolytic disease of the fetus and newborn is associated with significant morbidity and risk of death. With access to current, expert surveillance and interventions for Rhesus incompatible pregnancies, favourable outcomes for the fetus and neonate can be expected. Ongoing investigation of the long-term consequences for fetuses and neonates affected by Rhesus incompatibility will provide further opportunities to optimise the health of adult survivors of HDFN.
Source of funding
No specific grants from funding agencies in the public, commercial, or not-for-profit sectors were received.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
CRediT authorship contribution statement
Caroline Tyndall: Writing - original draft. Rocco Cuzzilla: Writing - review & editing. Stefan C. Kane: Supervision, Writing - review & editing.
Acknowledgements
None.
References (54)
- et al.
Erythroblastosis and reticulocytosis in anemic fetuses
Am J Obstet Gynecol
(1988) - et al.
Neutropenia and thrombocytopenia in infants with Rh hemolytic disease
J. Pediatr.
(1989) - et al.
531: Anti-Rh(D) Alloimmunization: outcomes at a single institution
Am J Obstet Gynecol
(2018) - et al.
Intrauterine transfusion-intraperitoneal versus intravascular approach: a case-control comparison
Am J Obstet Gynecol
(1990) - et al.
Management of fetal hemolytic disease by cordocentesis. II. Outcome of treatment
Am J Obstet Gynecol
(1991) - et al.
Porencephalic cyst: a complication of fetal intravascular transfusion
Am J Obstet Gynecol
(1991) - et al.
Outcome for children treated with fetal intravascular transfusions because of severe blood group antagonism
J. Pediatr.
(1997) - et al.
Intraperitoneal transfusion for severe, early-onset rhesus disease requiring treatment before 20 weeks of gestation: a consecutive case series
Eur J Obstet Gynecol Reprod Biol
(2020) - et al.
Suppression of erythropoiesis by intrauterine transfusions in hemolytic disease of the newborn: use of erythropoietin to treat the late anemia
J. Pediatr.
(1993) - et al.
Rhesus haemolytic disease of the newborn: postnatal management, associated morbidity and long-term outcome
Semin Fetal Neonatal Med
(2008)
The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatment
Am J Obstet Gynecol
Antenatal maternal administration of phenobarbital for the prevention of exchange transfusion in neonates with hemolytic disease of the fetus and newborn
Am J Obstet Gynecol
The clinical syndrome of bilirubin-induced neurologic dysfunction
Semin Perinatol
Long-term neurodevelopmental outcome after intrauterine transfusion for the treatment of fetal hemolytic disease
Am J Obstet Gynecol
Treatment of fetal erythroblastosis by intravascular transfusions: outcome at 6 years
Obstet Gynecol
Long-term neurodevelopmental outcome and brain volume after treatment for hydrops fetalis by in utero intravascular transfusion
Am J Obstet Gynecol
Management and prevention of red cell alloimmunization in pregnancy: a systematic review
Obstet Gynecol
Haemolytic disease of the fetus and newborn
Creasy & resnick’s maternal-fetal medicine: principles and practice
Serial study of bone marrow in hemolytic disease of the newborn (erythroblastosis fetalis)
Pediatrics
Relationship of fetal hemoglobin and oxygen content to lactate concentration in Rh isoimmunized pregnancies
Obstet Gynecol
Evaluation of hydrops fetalis
Severe fetal thrombocytopenia in Rhesus d alloimmunized pregnancies
Am J Obstet Gynecol
Fetal thrombocytopenia in pregnancies complicated by fetal anemia due to red-cell alloimmunization: cohort study and meta-analysis
J Perinatol
Management of rhesus alloimmunization in pregnancy
Obstet Gynecol
Red blood cell antibodies in pregnancy and their clinical consequences: synergistic effects of multiple specificities
Transfusion
Hemolytic disease of the fetus and newborn due to multiple maternal antibodies
Am J Obstet Gynecol
The near disappearance of fetal hydrops in relation to current state-of-the-art management of red cell alloimmunization
Prenat Diagn
Cited by (4)
Extension of Homo Sapiens Adapting to Every Environment with Divertgent Phenotypes: Blood Type Incompatible in Pregnancy as an Abaxial Phenomenon
2020, Transfusion and Apheresis ScienceCase report: Double filtration plasmapheresis (DFPP) for severe rhesus-D alloimmunization in two pregnant patients
2023, Frontiers in PediatricsHemolytic disease of the newborn, beyond the Rhesus disease
2022, Romanian Medical Journal